Ladenburg starts Rhythm Pharmaceuticals with Buy rating, $43 price target. Ladenburg Thalmann analyst Michael Higgins initiated coverage of Rhythm Pharmaceuticals with a Buy rating and $43 price target. Rhythm is developing setmelanotide, a novel weight-loss drug for ultra-orphan genetic obesity disorders caused by mutations in the melanocortin-4 receptor signaling pathway, Higgins tells investors in a research note. The analyst urges investors to accumulate a position ahead of upcoming 2019 milestones, particularly pro-opiomelanocortin and leptin receptor deficiency pivotal data in Q3. Target $43.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.